While chemotherapy sensitizers that block ABC transporters have not achieved significant results in clinical practice [58], the application of TTFields can normalize the concentration of chemotherapy drugs in drug-resistant cells overexpressing ABC transporters, similar to wild-type tumor cells [57]. The gene discussed is ABCG2; the disease is neoplasm.